Lindsey Roeker, MD
Hematology · Rochester, MNNPI 1497168538
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $93,250 of the $105,695 with a category attached, or 88.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2021 at $37,827 and has fallen 85.4% since, to $5,510 in 2025. Among hematology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1273.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Eli Lilly$17K
- AstraZeneca$16K
- Janssen Global Services, LLC$14K
- TG Therapeutics, Inc.$10K
- Beigene USA, Inc.$8K
- plus $18K from 8 others
Across 187 payments — averaging $51,243 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6.3M
- Genentech, Inc.$2.1M
- AstraZeneca$922K
- Adaptive Biotechnologies Corporation$271K
- Octapharma USA, Inc.$1K
What the payments were for
- Consulting fees$93,25088%
- Speaking & faculty fees$7,0487%
- Travel & lodging$3,3843%
- Food & beverage$1,9992%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $23,402 |
| Eli Lilly | 13 | $17,263 |
| AstraZeneca | 9 | $15,684 |
| Janssen Global Services, LLC | 8 | $13,543 |
| TG Therapeutics, Inc. | 9 | $10,357 |
| Beigene USA, Inc. | 3 | $7,747 |
| Lilly USA, LLC | 3 | $6,885 |
| Pfizer | 1 | $3,848 |
| Janssen Scientific Affairs, LLC | 2 | $2,778 |
| Genentech USA, Inc. | 2 | $1,974 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $1,489 |
| Astrazeneca UK Limited | 1 | $555 |
| Genentech, Inc. | 1 | $155 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,695 in reported general payments places this provider in the 90th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 134 | $1,929,123 |
| BrukinsaZanubrutinib | 53 | $654,311 |
| VenclextaVenetoclax | 30 | $395,486 |
| JakafiRuxolitinib Phosphate | 16 | $242,565 |
| Acyclovir | 59 | $847 |
| Allopurinol | 17 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $15,684 | $1,929,123134 claims |
| Beigene USA, Inc.Brukinsa | $7,747 | $654,31153 claims |
| AbbVieVenclexta | $23,402 | $395,48630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 hematology providers in Minnesota.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
- Thomas WitzigRochester$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.